New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2013
07:48 EDTPTXPernix Therapeutics shares could rebound on good execution, says Stifel
After Pernix reported much lower than expected Q1 revenue, Stifel lowered its price target on the stock to $4 from $10 but keeps a Buy rating on the shares based on valuation.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:04 EDTPTXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:30 EDTPTXDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
18:33 EDTPTXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Red Hat (RHT), up 4.6%... Five Below (FIVE), up 5.5%. ALSO HIGHER: Pernix Therapeutics (PTX), up 2.4% after being initiated with an Outperform at Oppenheimer. DOWN AFTER EARNINGS: Verint Systems (VRNT), down 2.3%... Pacific Sunwear (PSUN), down 5.9%. ALSO LOWER: Sucampo (SCMP), down 9.5% after filing to sell Class A common stock for holders... FutureFuel (FF) down 8% after "significant adverse impact" of P&G pact termination... Genesee & Wyoming (GWR), down 1.3% after lowering first quarter revenue guidance.
16:11 EDTPTXPernix Therapeutics initiated with an Outperform at Oppenheimer
Target $15.
March 12, 2015
10:01 EDTPTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:48 EDTPTXPernix Therapeutics downgraded to Hold from Buy at Cantor
Cantor Fitzgerald downgraded Pernix Therapeutics to Hold citing commercial execution risk following the company's acquisition of Zogenix's Zohydro ER franchise. Cantor lowered its price target for shares to $11 from $12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use